Boundless Bio is a clinical‑stage, next‑generation precision oncology company focused on developing therapeutics directed against extrachromosomal DNA (ecDNA) found in oncogene‑amplified cancers. Its lead program, BBI-355, is an orally available, potent, and selective CHK1 inhibitor identified via the company’s Spyglass research platform and designed to be synthetically lethal to ecDNA‑bearing cancer cells. BBI-355 is being evaluated in the ongoing Phase 1/2 POTENTIATE trial (NCT05827614) as a single agent and in combination with select therapies to determine safety, maximum tolerated dose, and recommended Phase 2 dose. The company is also advancing a preclinical pipeline of differentiated ecDNA‑directed therapy candidates. Boundless Bio is developing a proprietary ecDNA diagnostic clinical trial assay called ECHO (ecDNA Harboring Oncogenes) in partnership with SOPHiA GENETICS to support patient selection and development. The company will use new capital to fund clinical development, preclinical programs, and diagnostic assay advancement. Boundless Bio is a next-generation precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers. Its Spyglass™ platform combines proprietary ecDNA-driven and pair-matched tumor models with imaging and molecular analytical tools to interrogate ecDNA biology and discover targets that are synthetically lethal in ecDNA-driven tumors. From Spyglass, the company has discovered and validated three ecDNA-essential targets and has initiated drug discovery programs against each. Boundless is also developing the ECHO™ companion diagnostic to identify patients with ecDNA-driven tumors. The company plans to advance multiple ecDNA-directed therapeutic programs into the clinic and expand its pipeline of novel cancer therapies targeting ecDNA. Headquartered in San Diego and launched in 2019, Boundless says it will use the proceeds of its Series B to fund these clinical and pipeline activities. Boundless Bio is focused on interrogating and targeting extrachromosomal DNA (ecDNA) to create a new class of cancer medicines for tumors with high copy-number, focal gene amplifications. The company has developed technology to identify and characterize ecDNA-driven tumors and is using those tools to discover and validate novel cancer targets. Its initial programs are directed at high copy-number, focal gene amplification solid tumors, where ecDNA are believed to be primary drivers of growth, resistance, and recurrence. Leadership includes CEO Zachary Hornby and Chairman Jonathan Lim, and the scientific founders feature Paul Mischel and other academic leaders in cancer genomics and computational biology. Boundless Bio intends to exploit ecDNA’s unique vulnerabilities to develop targeted, proprietary therapies that counteract ecDNA-driven treatment evasion. The company completed a $46.4 million Series A financing to advance these efforts.

Total raised

$251M

Funding rounds

3

Latest round

Series C

Latest activity

May 2023